We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

SAFETY AND EFFICACY OF INSULIN DEGLUDEC/LIRAGLUTIDE FIXED-RATIO COMBINATION IN OAD FAILURE TYPE 2 DIABETES PATIENTS IN A TERTIARY CARE CENTRE IN EASTERN INDIA

Submitted

17 Views
0 Downloads
0 Saves

Presentation

thumbnail

Abstract

Abstract Body Background: In patients with uncontrolled type 2 diabetes despite receiving optimal dosage of multiple OADs, insulin may be initiated as per clinical practice guidelines. We evaluated the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) in such patients in a real world setting. Methods: A retrospective real world observational study from the author’s clinic database analysed the records of 30 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%) despite receiving optimal dose of three or more OADs. All these patients were treated with a fixed dose combination of insulin degludec and liraglutide known as iDegLira (Xultophy 100/3.6) along with metformin, unless contraindicated for a period of at least 12 weeks. Results: Significant improvement in FPG, PPPG and HbA1c was observed over the 12 week study period with 83.33% of the patients achieving their glycaemic targets. Mean IDegLira dose required 29 dose steps. Only one patient reported symptomatic hypoglycemia and none reported experience documented severe or nocturnal hypoglycaemia during the entire study period. No significant change in body weight was noted Conclusion: Administration of once daily IDegLira is an effective and safe option for OAD failure in Indian patients with low risk of hypoglycemia and no change in weight.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.